ZYBT

Zhengye Biotechnology Holding Limited (ZYBT) Economic Moat Analysis (2026)

Invetso Score: 2.2/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Intangible Assets

Score: 2.1 (Weak)

No provided evidence of proprietary brands, patents, or regulatory licenses that would let ZYBT charge meaningfully higher prices than peers over a 5–10 year horizon.

Negative TTM ROIC and ROCE indicate the company is not currently converting any intangible advantage into durable excess returns versus peers.

The absence of 5-year margin and return history in the supplied metrics limits evidence that any customer-recognized asset is sustaining pricing power relative to peers.

Without clear filing-based proof of protected IP or entrenched brand preference, the moat from intangible assets appears replicable and weak.

Switching Costs

Score:

The supplied metrics do not show retention, renewal, or embedded workflow data that would indicate customers face meaningful costs to leave ZYBT versus peers.

Negative ROIC and ROCE suggest customers are not locked in by a high-value, hard-to-replace solution that preserves margins through time.

A cash conversion cycle of 60.2 days does not by itself evidence switching costs, and it is not enough to show peer-leading stickiness.

In the absence of filing evidence for integration depth, contractual lock-in, or mission-critical usage, switching costs look low and easily substitutable.

Network Effects

Score:

No provided evidence indicates ZYBT operates a platform where more users, data, or transactions materially improve the product for other users.

Negative returns on capital argue against a self-reinforcing ecosystem that is translating scale into superior economics versus peers.

The supplied metrics do not show user growth, transaction density, or data advantages that would support a durable network effect.

Compared with peers that benefit from two-sided ecosystems or data flywheels, ZYBT has no demonstrated network-based moat in the information provided.

Cost Advantage

Score:

Negative TTM ROIC and ROCE indicate ZYBT is not currently operating with a cost structure that produces superior returns versus peers.

Asset turnover of 0.18 suggests low asset productivity, which weakens the case for a structural cost advantage.

The provided metrics do not show scale purchasing, manufacturing efficiency, or logistics advantages that would lower unit costs relative to peers.

Without evidence of persistent margin outperformance, any cost edge appears absent or not durable enough to support pricing power.

Efficient Scale

Score:

The supplied data do not show a concentrated niche, regulated bottleneck, or natural-monopoly structure that would let ZYBT earn excess returns as the market matures.

Negative returns on capital suggest the company is not yet capturing the economics typically associated with efficient scale versus peers.

No filing-based evidence was provided that rivals are constrained from entering or that the market is too small for multiple efficient competitors.

Compared with firms that benefit from local monopoly, infrastructure, or exchange-like positions, ZYBT shows no demonstrated efficient-scale moat in the available information.

Overall Score

Score:

ZYBT shows no demonstrated durable moat in the provided evidence, and negative ROIC/ROCE alongside weak asset efficiency suggests its competitive position is materially weaker than peers across the main moat drivers.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Zhengye Biotechnology Holding Limited. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →